TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33302802

Group type: EXPERIMENTAL
Intervention: 90 ml sea buckthorn puree for 90 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 33626904

Group type: EXPERIMENTAL
Intervention: Apixaban (early use at day 0 to 3 for TIA, day 3 to 5 for small AIS, day 7 to 9 for medium AIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apixaban (early use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (later use at 1 week post-TIA or 2 weeks post-AIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (later use)
Number of subjects: 0
Study: 32376110

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) hepatitis A vaccine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intramuscular (IM) hepatitis A vaccine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adverse events in SC group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Adverse events in IM group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Need for clotting factor concentrates due to adverse events in SC group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Need for clotting factor concentrates due to adverse events in IM group
Number of subjects: 78
Study: 35399854

Group type: EXPERIMENTAL
Intervention: CEUS combined with enhanced MR scanning
Number of subjects: 90

Group type: COMPARATOR
Intervention: CEUS
Number of subjects: 90
Study: 33621009

Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg BID
Number of subjects: 256

Group type: COMPARATOR
Intervention: Solifenacin 5mg orally once daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Combination of pregabalin and solifenacin
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 256
Study: 35027418

Group type: EXPERIMENTAL
Intervention: Quantitative Coronary Angiography (QCA)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 1528
Study: 34215498

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional chemoradiotherapy (CHRT)
Number of subjects: 100
Study: 32614232

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) measurement during psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance in psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyadic synchrony between patients and therapists
Number of subjects: 0
Study: 35925734

Group type: EXPERIMENTAL
Intervention: Metacognitive program (pediatric goal management training)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Psychoeducational program (pediatric brain health workshop)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 73
Study: 33620328

Group type: EXPERIMENTAL
Intervention: Program B (fixed order CBT-based stress management)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Program A (free-choice CBT-based stress management)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 949
Study: 33108935

Group type: EXPERIMENTAL
Intervention: Industry-sponsored trials
Number of subjects: 216

Group type: COMPARATOR
Intervention: Non-industry trials
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Industry trials
Number of subjects: 216
Study: 35296626

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% without benzalkonium chloride (BAK)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Latanoprost 0.005% with benzalkonium chloride (BAK)
Number of subjects: 578
Study: 32291094

Group type: EXPERIMENTAL
Intervention: Standard doses thromboprophylaxis
Number of subjects: 184
Study: 36267027

Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation (19.56 g day‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard prenatal care)
Number of subjects: 100
Study: 33618051

Group type: EXPERIMENTAL
Intervention: Interval exercise (IE) - 30 min at 100% peak work capacity (WRpeak) for 30s alternated with 40% WRpeak for 30s, 3 times weekly for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interval exercise (IE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant-load exercise (CLE) - 30 min at 70% WRpeak, 3 times weekly for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant-load exercise (CLE)
Number of subjects: 24
Study: 36093101

Group type: EXPERIMENTAL
Intervention: Nomogram for cumulative live birth (CLB) prediction
Number of subjects: 26689
Study: 34009282

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT) for 12 weeks (n = 51)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control condition (n = 51)
Number of subjects: 102
Study: 32386068

Group type: EXPERIMENTAL
Intervention: Noncultured epidermal cell suspension (NCES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Suction blister epidermal grafting (SBEG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mini punch grafting (MPG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Color matching and patient satisfaction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between NCES and MPG, SBEG and MPG
Number of subjects: 30
Study: 36328040

Group type: EXPERIMENTAL
Intervention: Isatuximab plus lenalidomide, bortezomib, and dexamethasone
Number of subjects: 660

Group type: COMPARATOR
Intervention: Lenalidomide, bortezomib, and dexamethasone (control group)
Number of subjects: 660
Study: 33560426

Group type: EXPERIMENTAL
Intervention: AppyCDS intervention
Number of subjects: 5938
Study: 34416295

Group type: EXPERIMENTAL
Intervention: Detoxifying and blood-activating Chinese medicine granules (15 g of Polygonum cuspidatum and 10 g of Crataegus pinnatifida for 4 weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standardized Western medicine (control group)
Number of subjects: 144
Study: 32370760

Group type: EXPERIMENTAL
Intervention: Increased non-alcoholic drinks (six non-alcoholic, two alcoholic drinks)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Reference 1 (two non-alcoholic, two alcoholic drinks)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Reference 2 (four non-alcoholic, four alcoholic drinks)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Increased alcoholic drinks (two non-alcoholic, six alcoholic drinks)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Reference 1 to Increased non-alcoholic drinks condition
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Reference 2 to Increased non-alcoholic drinks condition
Number of subjects: 808
Study: 35648209

Group type: EXPERIMENTAL
Intervention: Recombined Contrast-Enhanced Mammography (rCEM)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard Assessment (SA)
Number of subjects: 220
Study: 34210325

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal samples
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Blood samples
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Urine samples
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stool samples
Number of subjects: 100
Study: 33074557

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 0.5 mg
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 1.0 mg
Number of subjects: 868

Group type: COMPARATOR
Intervention: Once-daily sitagliptin 100 mg
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Both doses of semaglutide
Number of subjects: 868
Study: 33888407

Group type: EXPERIMENTAL
Intervention: Sunlight exposure (5 days a week for 4 weeks, average duration 21 ± 5 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No sunlight exposure (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Number of subjects: 40
Study: 33314690

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) ablation
Number of subjects: 194
Study: 33730209

Group type: EXPERIMENTAL
Intervention: 1.5K1:5P
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5K1:5P
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3.5K1:5P
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.5K1:4P
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.5K1:3P
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.5K1:5A
Number of subjects: 10
Study: 32703769

Group type: EXPERIMENTAL
Intervention: Asparaginase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic GSK3α inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal intestinal progenitors
Number of subjects: 0
Study: 34269326

Group type: EXPERIMENTAL
Intervention: ZXR00 IOL
Number of subjects: 299
Study: 34380638

Group type: EXPERIMENTAL
Intervention: OncoMasTR Risk Score
Number of subjects: 1200
Study: 32758231

Group type: EXPERIMENTAL
Intervention: Placental malaria (IFN-β and IL-10 expression) in multigravidas
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IFN-β levels in multigravidas with placental malaria
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IFN-β levels in general
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uninfected controls (gravidity-matched)
Number of subjects: 40
Study: 33026160

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg (ExQW)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 32341326

Group type: EXPERIMENTAL
Intervention: Hypothyroidism group
Number of subjects: 69584
Study: 33479111

Group type: EXPERIMENTAL
Intervention: Genotype-directed prescribing
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Genotype-directed prescribing (AA genotype)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard guideline care
Number of subjects: 241
Study: 32210849

Group type: EXPERIMENTAL
Intervention: Multimodal speech-gesture training (MSG training), 8 sessions of 60 minutes each.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group, N=20.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls, N=30.
Number of subjects: 30
Study: 36229952

Group type: EXPERIMENTAL
Intervention: Medium energy level (energy level 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High energy level (energy level 5)
Number of subjects: 20
Study: 33441146

Group type: EXPERIMENTAL
Intervention: Glycopyrronium/indacaterol (Gly/Ind)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (Ume/Vil)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tiotropium/olodaterol (Tio/Olo)
Number of subjects: 75
Study: 32289301

Group type: EXPERIMENTAL
Intervention: Online‐MUF
Number of subjects: 99

Group type: COMPARATOR
Intervention: Offline‐MUF
Number of subjects: 99

Group type: COMPARATOR
Intervention: Centrifugation
Number of subjects: 99
Study: 35642157

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) - 1 Hz, 15 min, 5 d/week for 2 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT) - corresponding movements of limbs, 15 min, 5 d/week for 2 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 34151880

Group type: EXPERIMENTAL
Intervention: CESM-based radiomics model using low energy images
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CESM-based radiomics model using subtracted images
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Combined model using low energy and subtracted images
Number of subjects: 205
Study: 32209798

Group type: EXPERIMENTAL
Intervention: Nordic walking exercise (NW) for 12 weeks, 1 hour 3 times a week at 60-70% of maximal heart rate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified lower-calorie diet (MD) for 12 weeks, reducing daily energy intake by 30%
Number of subjects: 30
Study: 35437136

Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver with chest compression
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver with cervical stabilization
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver without chest compression
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jaw-thrust maneuver without cervical stabilization
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard method with chest compression
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard method with cervical stabilization
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard method without chest compression
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard method without cervical stabilization
Number of subjects: 11
Study: 33187020

Group type: EXPERIMENTAL
Intervention: Volatile general anaesthesia (GA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol GA combined with paravertebral regional anaesthesia (PPA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 32496449

Group type: EXPERIMENTAL
Intervention: Atropine 0.004 mg/kg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120
Study: 33188598

Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Incomplete Revascularization (ICR)
Number of subjects: 1859
Study: 32898569

Group type: EXPERIMENTAL
Intervention: Desensitization with Carfilzomib (27mg/m2 IV) and Lulizumab (12.5mg/kg SC) over four weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: No desensitization (Control)
Number of subjects: 10
Study: 32645683

Group type: EXPERIMENTAL
Intervention: Active tACS (10 Hz, 2 mA, 30 min) combined with ABM
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham tACS combined with ABM
Number of subjects: 19
Study: 35086737

Group type: EXPERIMENTAL
Intervention: pharmacogenomic-driven chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard adjuvant chemotherapy
Number of subjects: 0
Study: 33314605

Group type: EXPERIMENTAL
Intervention: Multi-layered silicone foam
Number of subjects: 135

Group type: COMPARATOR
Intervention: Transparent polyurethane film
Number of subjects: 135
Study: 34768502

Group type: EXPERIMENTAL
Intervention: Hypopressive abdominal gymnastics (HAG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 32536013

Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg twice daily) plus nonsteroidal aromatase inhibitor (NSAI)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo plus nonsteroidal aromatase inhibitor (NSAI)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus NSAI
Number of subjects: 493
Study: 35266417

Group type: EXPERIMENTAL
Intervention: Ofatumumab (20 mg subcutaneously every 4 weeks)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Teriflunomide (14 mg orally once daily)
Number of subjects: 615
Study: 32272959

Group type: EXPERIMENTAL
Intervention: 12.5 μg misoprostol sublingually
Number of subjects: 200

Group type: COMPARATOR
Intervention: 25 μg misoprostol vaginally
Number of subjects: 200
Study: 35086385

Group type: EXPERIMENTAL
Intervention: Orbital atherectomy (OA) with adjunctive drug-coated balloon (DCB) angioplasty
Number of subjects: 66

Group type: COMPARATOR
Intervention: Plain balloon angioplasty (BA) and DCB angioplasty (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 34837899

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) intervention, 6 sessions every 2 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 35655176

Group type: EXPERIMENTAL
Intervention: Relaxing breathing
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Relaxing breathing paired with cardiac biofeedback
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 36296976

Group type: EXPERIMENTAL
Intervention: Web resource (access to IBD-specific diet concerns) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no access to web resource) for 12 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Web resource
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 33212988

Group type: EXPERIMENTAL
Intervention: Mental health variables (psychological symptoms, financial difficulties, psychological disorders)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Physical and mental disorders
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Greater number of psychological symptoms
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Mental health
Number of subjects: 555
Study: 35041337

Group type: COMPARATOR
Intervention: Resection of the primary (RP) in small intestine tumors
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Resection of the primary (RP) in lung tumors
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Resection of the primary (RP) in pancreas tumors
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Resection of the primary (RP) overall
Number of subjects: 2361
Study: 35973395

Group type: EXPERIMENTAL
Intervention: P1016 (endopeptidase)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 32920647

Group type: EXPERIMENTAL
Intervention: BUP‐XR (extended-release subcutaneous buprenorphine)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 454
Study: 32272973

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU)
Number of subjects: 24
Study: 35853489

Group type: EXPERIMENTAL
Intervention: Monthly injection of pegcetacoplan (AM)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Injection every other month of pegcetacoplan (AEOM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sham control (SM)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 113
Study: 34342501

Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MRI-prompted core-needle biopsies (CNBs)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MRI features
Number of subjects: 339
Study: 33010126

Group type: EXPERIMENTAL
Intervention: Training program and pain management protocol (after intervention)
Number of subjects: 261
Study: 36395809

Group type: EXPERIMENTAL
Intervention: Single-fraction SABR (SF)
Number of subjects: 87
Study: 33958326

Group type: EXPERIMENTAL
Intervention: IXE Q4W
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IXE Q2W
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined IXE
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 155
Study: 32401905

Group type: EXPERIMENTAL
Intervention: Nursing intervention to reduce alcohol use
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Nursing intervention to increase HIV knowledge
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Nursing intervention to increase condom use self-efficacy
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 132
Study: 36367998

Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZA) 160 mg once daily for 6 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZA)
Number of subjects: 86
Study: 33432386

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence angiography (FA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) sentinel lymph node (SLN) detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) visualization
Number of subjects: 0
Study: 34666767

Group type: EXPERIMENTAL
Intervention: JTA-200/2 (200 μg clonidine and 20 mg hyaluronic acid in 2 ml)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: JTA-004 (pooled data from all formulations)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Reference treatment (hylan G-F 20)
Number of subjects: 164
Study: 33212467

Group type: EXPERIMENTAL
Intervention: Sex Workers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study: 34922888

Group type: EXPERIMENTAL
Intervention: Distal transradial approach (dTRA)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Traditional transradial approach (TRA)
Number of subjects: 1042
Study: 34108127

Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib/dexamethasone (D‐Vd)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 211
Study: 35794728

Group type: EXPERIMENTAL
Intervention: Coloring therapy combined with conventional therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional antianxiety medication and physical therapy
Number of subjects: 88
Study: 34039734

Group type: EXPERIMENTAL
Intervention: Femoral triangle block and iPACK
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local infiltration analgesia
Number of subjects: 60
Study: 32362479

Group type: EXPERIMENTAL
Intervention: Flurbiprofen patch (FPP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: S-Flurbiprofen patch (SFPP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no patch)
Number of subjects: 79
Study: 36323482

Group type: EXPERIMENTAL
Intervention: Stepped care approach including app-intervention, two telephone counselling sessions (50 min each), and online therapy over 17 weeks (15 weekly group sessions, 8 individual sessions).
Number of subjects: 860

Group type: COMPARATOR
Intervention: Placebo condition (details not specified in the abstract).
Number of subjects: 860
Study: 34266940

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 and 300 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33079959

Group type: EXPERIMENTAL
Intervention: Salmonella Typhi (104 CFU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmonella Paratyphi A (103 CFU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous exposure to Salmonella Typhi or Paratyphi A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naïve controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterologous re-challenge with Salmonella Typhi or Salmonella Paratyphi A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior exposure
Number of subjects: 0